Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of petrelintide monotherapy

Next Previous
Trial Profile

A phase III trial of petrelintide monotherapy

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Petrelintide (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 07 May 2026 According to Zealand Pharma media release, company expects to receive milestone payments of USD 700 million from Roche , including USD 575 million linked to the initiation of Phase 3 trials with petrelintide monotherapy.
  • 07 May 2026 According to Zealand Pharma media release, Zealand Pharma and Roche expect to initiate registrational Phase 3 trials with petrelintide monotherapy.
  • 19 Feb 2026 According to Zealand Pharma media release, Phase 3 program expected to initiate in the second half of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top